At Sanwa BioTech, we believe that impending changes are coming to the way to conventional clinical diagnostic & academic R&D for bio-discoveries. We aim to become a driving force for these changes to revolutionize healthcare solutions into the future. Sanwa BioTech delivers accurate and actionable information through our disposable Lab-On-Chip (LOC) rapid diagnostic platform, resulting in transformative diagnostic tests for faster clinical decisions and better economic outcomes.
At Sanwa Biotech, we provide diagnostic solutions based on our microfluidic disposable Lab-On-Chip (LOC) platform, including an integrative point of care device, reagents, software analytics & data management service, which brings convenience and value in diseases monitoring and supports clinical decisions, improves patients health and contributes to innovative solutions that combat challenges on global health care.
Contact
Unit 627, 6/F, BioTech Centre Two,
No.11 Science Park West Avenue,
Hong Kong Science Park,
Shatin, Hong Kong SAR,
CHINA
Unit 2, 5/F.,
Wah Lai Industrial Centre,
10-14 Kwei Tei Street,
Fo Tan, Hong Kong SAR,
CHINA
Tel: +852 2698 9903
Website: http://sanwabiotech.com/en/index.html
Email: inquiry@sanwabiotech.com
Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and…
Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong…
Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning…
Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative…
Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy…
Kelvin Chiu and Isabelle Dutry of Sanwa BioTech in Hong Kong highlight the critical importance of personalised fast-track diagnostics in countering the COVID-19 pandemic, the role that Asian firms have…
Michael Chan, Senior Vice President of Global Issuer Services for the Hong Kong Exchange (HKEX) highlights the vibrancy and diversity that biotechs have brought to the market, HKEX’s three unique…
See our Cookie Privacy Policy Here
